Last reviewed · How we verify
MP-214
At a glance
| Generic name | MP-214 |
|---|---|
| Sponsor | Tanabe Pharma Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Long-Term Study of MP-214 in Patients With Receiving Multiple Drugs Schizophrenia (PHASE2, PHASE3)
- A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia (PHASE2, PHASE3)
- Long-Term Study of MP-214 in Patients With Schizophrenia (PHASE2, PHASE3)
- A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia (PHASE2, PHASE3)
- Safety, Pharmacokinetics and Efficacy Study of MP-214 in Patients With Schizophrenia (PHASE2)
- Safety and Efficacy of MP-214 in Patients With Schizophrenia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP-214 CI brief — competitive landscape report
- MP-214 updates RSS · CI watch RSS
- Tanabe Pharma Corporation portfolio CI